BAM
IOVA icon

Bellevue Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bellevue Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78
Closed -$1K – 517
2022
Q1 		$1K Sell
78
-14
-15% -$217 ﹤0.01% 514
2021
Q4 		$2K Sell
92
-7
-7% -$154 ﹤0.01% 498
2021
Q3 		$2K Hold
99
– – ﹤0.01% 522
2021
Q2 		$3K Sell
99
-9
-8% -$234 ﹤0.01% 454
2021
Q1 		$3K Sell
108
-16
-13% -$663 ﹤0.01% 515
2020
Q4 		$6K Sell
124
-41
-25% -$1.63K ﹤0.01% 392
2020
Q3 		$5K Buy
165
+38
+30% +$1.17K ﹤0.01% 388
2020
Q2 		$3K Hold
127
– – ﹤0.01% 479
2020
Q1 		$5K Buy
127
+52
+69% +$1.38K 0.01% 387
2019
Q4 		$2K Buy
+75
New +$1.71K ﹤0.01% 438

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Bellevue Asset Management's IOVA Position: Q2 2022 in Review

Bellevue Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2022, closing a stake of 78 shares — an estimated $1K sold.

Bellevue Asset Management first reported a position in IOVA in Q4 2019 and held it in 10 quarters. The position peaked at $6K in Q4 2020. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

  • Bellevue Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Bellevue Asset Management sold 78 Iovance Biotherapeutics shares in Q2 2022, an estimated $1K.
  • Bellevue Asset Management first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 10 quarters.
  • Bellevue Asset Management's Iovance Biotherapeutics position peaked at $6K in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Bellevue Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.